Publication details

Antikoagulační terapie a fibrilace síní

Title in English Anticoagulant therapy and atrial fibrillation
Authors

LÁBROVÁ Růžena ŠPINAR Jindřich

Year of publication 2012
Type Article in Periodical
Magazine / Source Kardiologická revue
MU Faculty or unit

Faculty of Medicine

Citation
Field Cardiovascular diseases incl. cardiosurgery
Keywords atrial fibrillation; CHA2DS2-VASc-VASc score; warfarin; novel anticoagulants; dabigatran; apixaban; rivaroxaban; edoxaban
Description Atrial fibrillation is the most frequent supraventricular arrythmia and is associated with increased morbidity and mortality. Patients with any form of atrial fibrillation have significantly higher risk of stroke and systemic embolism. Therefore, anticoagulation therapy is needed to prevent and treat cardioembolic events in such patients. According to updated 2010 European Guidelines for Diagnosis and Treatment of atrial fibrillation, the patients should be stratified and indicated to anticoagulation therapy based on their risk of stroke using the CHA2 DS2 -VASc scoring system but with regards to their bleeding risk as calculated by the HAS-BLED score. Novel anticoagulant agents that interfere with the coagulation cascade at different levels and have markable advantages over vitamin K antagonist - warfarin have been developed. These include a direct thrombin inhibitor dabigatran (RE-LY study), factor Xa inhibitors rivaroxaban (Rocket AF study) and apixaban (AVERROES, ARISTOTLE studies). Another anti-Xa agent edoxaban is being tested in a large clinical trial (ENGAGE).

You are running an old browser version. We recommend updating your browser to its latest version.

More info